Sorrento Therapeutics (NASDAQ: SRNE) and Intrexon (NYSE:XON) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, profitability, dividends, analyst recommendations, risk, valuation and institutional ownership.

Volatility and Risk

Sorrento Therapeutics has a beta of 2.43, suggesting that its stock price is 143% more volatile than the S&P 500. Comparatively, Intrexon has a beta of 1.11, suggesting that its stock price is 11% more volatile than the S&P 500.

Valuation & Earnings

This table compares Sorrento Therapeutics and Intrexon’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Sorrento Therapeutics $151.85 million 3.78 $9.13 million ($1.14) -5.53
Intrexon $230.98 million 10.02 -$117.01 million ($0.92) -19.50

Sorrento Therapeutics has higher earnings, but lower revenue than Intrexon. Intrexon is trading at a lower price-to-earnings ratio than Sorrento Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Sorrento Therapeutics and Intrexon’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Sorrento Therapeutics 29.72% 38.43% 11.15%
Intrexon -50.61% -16.94% -10.47%

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Sorrento Therapeutics and Intrexon, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sorrento Therapeutics 0 0 6 0 3.00
Intrexon 0 2 4 0 2.67

Sorrento Therapeutics currently has a consensus target price of $15.33, indicating a potential upside of 143.39%. Intrexon has a consensus target price of $34.67, indicating a potential upside of 93.24%. Given Sorrento Therapeutics’ stronger consensus rating and higher possible upside, equities analysts clearly believe Sorrento Therapeutics is more favorable than Intrexon.

Insider & Institutional Ownership

11.1% of Sorrento Therapeutics shares are held by institutional investors. Comparatively, 76.0% of Intrexon shares are held by institutional investors. 5.0% of Sorrento Therapeutics shares are held by insiders. Comparatively, 55.1% of Intrexon shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Sorrento Therapeutics beats Intrexon on 9 of the 14 factors compared between the two stocks.

Sorrento Therapeutics Company Profile

Sorrento Therapeutics, Inc., a clinical stage biotechnology company, primarily engages in the discovery and development of therapies focused on oncology and the treatment of chronic cancer pain worldwide. It develops therapeutic products for the treatment of auto-immune, inflammatory, neurodegenerative, and infectious diseases. The company offers resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for the treatment of intractable pain at end-stage disease. Its preclinical human therapeutic antibodies include antibody drug conjugates, bispecific approaches, and T-Cell Receptor, as well as Chimeric Antigen Receptor-T Cell (CAR-T) for adoptive cellular immunotherapy for the treatment of solid and liquid tumors. It is also involved in the development of T-007, an anti-CD38 CAR-T cellular therapy for the treatment of multiple myeloma, as well as for additional potential indications, such as amyloidosis and graft-versus-host disease; and T-009, an anti-CD123 CAR-T cellular therapy for the treatment of acute myelogenous leukemia. The company has license and collaboration agreement with Les Laboratoires Servier for the development, manufacture, and commercialization of products using its human immuno-oncology anti-PD-1 mAb STI-A1110. Sorrento Therapeutics, Inc. was founded in 2006 and is based in San Diego, California.

Intrexon Company Profile

Intrexon Corporation operates in the synthetic biology field in the United States. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components. Its technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing; and ActoBiotics and AdenoVerse technology platforms. The company also provides reproductive technologies and other genetic processes to cattle breeders and producers; biological insect control solutions; technologies for non-browning apple without the use of any flavor-altering chemical or antioxidant additives; commercial aquaculture products; genetic preservation and cloning technologies; genetically engineered swine for medical and genetic research; and artwork, children's toys, and novelty goods that are derived from living organisms or enabled by synthetic biology. It serves health, food, energy, environment, and consumer markets. Intrexon Corporation has collaboration and license agreements with ZIOPHARM Oncology, Inc.; Oragenics, Inc.; Fibrocell Science, Inc.; Genopaver, LLC; S & I Ophthalmic, LLC; OvaXon, LLC; Intrexon Energy Partners, LLC; Persea Bio, LLC; Ares Trading S.A.; Intrexon Energy Partners II, LLC; Intrexon T1D Partners, LLC; AquaBounty Technologies, Inc.; Thrive Agrobiotics, Inc.; Exotech Bio, Inc.; Relieve Genetics, Inc.; AD Skincare, Inc.; Genten Therapeutics, Inc.; and CRS Bio, Inc. The company was formerly known as Genomatix Ltd. and changed its name to Intrexon Corporation in 2005. Intrexon Corporation was founded in 1998 and is based in Germantown, Maryland.

Receive News & Ratings for Sorrento Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sorrento Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.